{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:56:41Z","timestamp":1781902601652,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03128-2","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T06:02:34Z","timestamp":1658556154000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New endpoints in adrenocortical carcinoma studies: a mini review"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-0792","authenticated-orcid":false,"given":"Matthieu","family":"Faron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Segolene","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Libe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"3128_CR1","volume-title":"BEST (Biomarkers, EndpointS, and Other Tools) Resource","author":"FDA-NIH Biomarker Working Group.","year":"2016","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource (Food and Drug Administration (US), Silver Spring (MD), 2016)"},{"key":"3128_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/1467-9876.00244","volume":"50","author":"T Burzykowski","year":"2001","unstructured":"T. Burzykowski, G. Molenberghs, M. Buyse, H. Geys, D. Renard, Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J. R. Stat. Soc.: Ser. C. (Appl. Stat.) 50, 405\u2013422 (2001). https:\/\/doi.org\/10.1111\/1467-9876.00244","journal-title":"J. R. Stat. Soc.: Ser. C. (Appl. Stat.)"},{"key":"3128_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"M. Buyse, G. Molenberghs, T. Burzykowski, D. Renard, H. Geys, The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1, 49\u201367 (2000). https:\/\/doi.org\/10.1093\/biostatistics\/1.1.49","journal-title":"Biostatistics"},{"key":"3128_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189\u20132197 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N. Engl. J. Med."},{"key":"3128_CR5","doi-asserted-by":"publisher","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","volume":"5","author":"M Terzolo","year":"2021","unstructured":"M. Terzolo, M. Fassnacht, P. Perotti, R. Libe, A. Lacroix, D. Kastelan et al. Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J. Endocr. Soc. 5, A166\u2013A167 (2021). https:\/\/doi.org\/10.1210\/jendso\/bvab048.336","journal-title":"J. Endocr. Soc."},{"key":"3128_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"M. Fassnacht, A. Berruti, E. Baudin, M.J. Demeure, J. Gilbert, H. Haak et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426\u2013435 (2015). https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1","journal-title":"Lancet Oncol."},{"key":"3128_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1","volume":"20","author":"JJH Park","year":"2019","unstructured":"J.J.H. Park, E. Siden, M.J. Zoratti, L. Dron, O. Harari, J. Singer et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20, 572 (2019). https:\/\/doi.org\/10.1186\/s13063-019-3664-1","journal-title":"Trials"},{"key":"3128_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","volume":"25","author":"P Icard","year":"2001","unstructured":"P. Icard, P. Goudet, C. Charpenay, B. Andreassian, B. Carnaille, Y. Chapuis et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg. 25, 891\u2013897 (2001). https:\/\/doi.org\/10.1007\/s00268-001-0047-y","journal-title":"World J. Surg."},{"key":"3128_CR9","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","volume":"26","author":"R Lib\u00e9","year":"2015","unstructured":"R. Lib\u00e9, I. Borget, C.L. Ronchi, B. Zaggia, M. Kroiss, T. Kerkhofs et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann. Oncol. 26, 2119\u20132125 (2015). https:\/\/doi.org\/10.1093\/annonc\/mdv329","journal-title":"Ann. Oncol."},{"key":"3128_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1530\/EJE-21-0510","volume":"186","author":"YS Elhassan","year":"2021","unstructured":"Y.S. Elhassan, B. Altieri, S. Berhane, D. Cosentini, A. Calabrese, M. Haissaguerre et al. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur. J. Endocrinol. 186, 25\u201336 (2021). https:\/\/doi.org\/10.1530\/EJE-21-0510","journal-title":"Eur. J. Endocrinol."},{"key":"3128_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","volume":"13","author":"LM Weiss","year":"1989","unstructured":"L.M. Weiss, L.J. Medeiros, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202\u2013206 (1989). https:\/\/doi.org\/10.1097\/00000478-198903000-00004","journal-title":"Am. J. Surg. Pathol."},{"key":"3128_CR12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","volume":"27","author":"A de Reyni\u00e8s","year":"2009","unstructured":"A. de Reyni\u00e8s, G. Assi\u00e9, D.S. Rickman, F. Tissier, L. Groussin, F. Ren\u00e9-Corail et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108\u20131115 (2009). https:\/\/doi.org\/10.1200\/JCO.2008.18.5678","journal-title":"J. Clin. Oncol."},{"key":"3128_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009). https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur. J. Cancer"},{"key":"3128_CR14","doi-asserted-by":"publisher","first-page":"E1395","DOI":"10.3390\/cancers12061395","volume":"12","author":"R Ambrosini","year":"2020","unstructured":"R. Ambrosini, M.C. Balli, M. Lagan\u00e0, M. Bertuletti, L. Bottoni, F. Vaccher et al. Adrenocortical carcinoma and CT assessment of therapy response: the value of combining multiple criteria. Cancers 12, E1395 (2020). https:\/\/doi.org\/10.3390\/cancers12061395","journal-title":"Cancers"},{"key":"3128_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D.J. Gross et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr. Relat. Cancer 12, 657\u2013666 (2005). https:\/\/doi.org\/10.1677\/erc.1.01025","journal-title":"Endocr. Relat. Cancer"},{"key":"3128_CR16","doi-asserted-by":"publisher","first-page":"E941","DOI":"10.3390\/cancers12040941","volume":"12","author":"M Lagan\u00e0","year":"2020","unstructured":"M. Lagan\u00e0, S. Grisanti, D. Cosentini, V.D. Ferrari, B. Lazzari, R. Ambrosini et al. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience. Cancers 12, E941 (2020). https:\/\/doi.org\/10.3390\/cancers12040941","journal-title":"Cancers"},{"key":"3128_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1677\/ERC-09-0341","volume":"17","author":"P Malandrino","year":"2010","unstructured":"P. Malandrino, A. Al Ghuzlan, M. Castaing, J. Young, B. Caillou, J.-P. Travagli et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer 17, 797\u2013807 (2010). https:\/\/doi.org\/10.1677\/ERC-09-0341","journal-title":"Endocr. Relat. Cancer"},{"key":"3128_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"M. Fassnacht, S. Johanssen, M. Quinkler, P. Bucsky, H.S. Willenberg, F. Beuschlein et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115, 243\u2013250 (2009). https:\/\/doi.org\/10.1002\/cncr.24030","journal-title":"Cancer"},{"key":"3128_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","volume":"38","author":"N Raj","year":"2020","unstructured":"N. Raj, Y. Zheng, V. Kelly, S.S. Katz, J. Chou, R.K.G. Do et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38, 71\u201380 (2020). https:\/\/doi.org\/10.1200\/JCO.19.01586","journal-title":"J. Clin. Oncol."},{"key":"3128_CR20","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.2014.55.2836","volume":"32","author":"A Berruti","year":"2014","unstructured":"A. Berruti, V. Amoroso, F. Gallo, V. Bertaglia, E. Simoncini, R. Pedersini et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J. Clin. Oncol. 32, 3883\u20133891 (2014). https:\/\/doi.org\/10.1200\/JCO.2014.55.2836","journal-title":"J. Clin. Oncol."},{"key":"3128_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","volume":"5","author":"AM Lerario","year":"2014","unstructured":"A.M. Lerario, F.P. Worden, C.A. Ramm, E.A. Hesseltine, E.A. Hasseltine, W.M. Stadler et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm. Cancer 5, 232\u2013239 (2014). https:\/\/doi.org\/10.1007\/s12672-014-0182-1","journal-title":"Horm. Cancer"},{"key":"3128_CR22","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"M. Kroiss, M. Quinkler, S. Johanssen, N.P. van Erp, N. Lankheet, A. P\u00f6llinger et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J. Clin. Endocrinol. Metab. 97, 3495\u20133503 (2012). https:\/\/doi.org\/10.1210\/jc.2012-1419","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"A. Berruti, P. Sperone, A. Ferrero, A. Germano, A. Ardito, A.M. Priola et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 166, 451\u2013458 (2012). https:\/\/doi.org\/10.1530\/EJE-11-0918","journal-title":"Eur. J. Endocrinol."},{"key":"3128_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"M.A. Habra, B. Stephen, M. Campbell, K. Hess, C. Tapia, M. Xu et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer 7, 253 (2019). https:\/\/doi.org\/10.1186\/s40425-019-0722-x","journal-title":"J. Immunother. Cancer"},{"key":"3128_CR25","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O\u2019Sullivan","year":"2014","unstructured":"C. O\u2019Sullivan, M. Edgerly, M. Velarde, J. Wilkerson, A.M. Venkatesan, S. Pittaluga et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J. Clin. Endocrinol. Metab. 99, 1291\u20131297 (2014). https:\/\/doi.org\/10.1210\/jc.2013-2298","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR26","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1210\/jc.2019-00600","volume":"104","author":"BA Carneiro","year":"2019","unstructured":"B.A. Carneiro, B. Konda, R.B. Costa, R.L.B. Costa, V. Sagar, D.B. Gursel et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J. Clin. Endocrinol. Metab. 104, 6193\u20136200 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00600","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR27","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"I.G. Hermsen, M. Fassnacht, M. Terzolo, S. Houterman, J. den Hartigh, S. Leboulleux et al. Plasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J. Clin. Endocrinol. Metab. 96, 1844\u20131851 (2011). https:\/\/doi.org\/10.1210\/jc.2010-2676","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"F. Megerle, W. Herrmann, W. Schloetelburg, C.L. Ronchi, A. Pulzer, M. Quinkler et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 103, 1686\u20131695 (2018). https:\/\/doi.org\/10.1210\/jc.2017-02591","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR29","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"D.L. Reidy-Lagunes, B. Lung, B.R. Untch, N. Raj, A. Hrabovsky, C. Kelly et al. Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014a new look at an old drug. Oncologist 22, 1102\u20131106 (2017). https:\/\/doi.org\/10.1634\/theoncologist.2016-0459","journal-title":"Oncologist"},{"key":"3128_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12672-017-0313-6","volume":"9","author":"D Vezzosi","year":"2018","unstructured":"D. Vezzosi, C. Do Cao, S. Hescot, J. Bertherat, M. Haissaguerre, V. Bongard et al. Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm. Cancer 9, 62\u201369 (2018). https:\/\/doi.org\/10.1007\/s12672-017-0313-6","journal-title":"Horm. Cancer"},{"key":"3128_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ando.2016.10.001","volume":"78","author":"S Hescot","year":"2017","unstructured":"S. Hescot, S. Leboulleux, C. Caramella, A. Paci, M. Lombes, A. Berdelou et al. Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient. Ann. Endocrinol. 78, 67\u201369 (2017). https:\/\/doi.org\/10.1016\/j.ando.2016.10.001","journal-title":"Ann. Endocrinol."},{"key":"3128_CR32","doi-asserted-by":"publisher","first-page":"e4698","DOI":"10.1210\/clinem\/dgab449","volume":"106","author":"A Boil\u00e8ve","year":"2021","unstructured":"A. Boil\u00e8ve, E. Mathy, C. Roux, M. Faron, J. Hadoux, L. Tselikas et al. Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 106, e4698\u2013e4707 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab449","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3128_CR33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/annonc\/mdz170","volume":"30","author":"J-Y Blay","year":"2019","unstructured":"J.-Y. Blay, C. Honor\u00e9, E. Stoeckle, P. Meeus, M. Jafari, F. Gouin et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann. Oncol. 30, 1407 (2019). https:\/\/doi.org\/10.1093\/annonc\/mdz170","journal-title":"Ann. Oncol."},{"key":"3128_CR34","doi-asserted-by":"publisher","first-page":"E1500","DOI":"10.3390\/cancers11101500","volume":"11","author":"RV Steenaard","year":"2019","unstructured":"R.V. Steenaard, L.A. Michon, H.R. Haak, Health-related quality of life in adrenocortical carcinoma. Cancers 11, E1500 (2019). https:\/\/doi.org\/10.3390\/cancers11101500","journal-title":"Cancers"},{"key":"3128_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/s0959-8049(00)00447-0","volume":"37","author":"R Schwarz","year":"2001","unstructured":"R. Schwarz, A. Hinz, Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur. J. Cancer 37, 1345\u20131351 (2001). https:\/\/doi.org\/10.1016\/s0959-8049(00)00447-0","journal-title":"Eur. J. Cancer"},{"key":"3128_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/j.1365-2265.2011.04191.x","volume":"76","author":"M Milian","year":"2012","unstructured":"M. Milian, P. Teufel, J. Honegger, B. Gallwitz, G. Schnauder, T. Psaras, The development of the Tuebingen Cushing\u2019s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin. Endocrinol. 76, 851\u2013860 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04191.x","journal-title":"Clin. Endocrinol."},{"key":"3128_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1530\/EJE-07-0762","volume":"158","author":"SM Webb","year":"2008","unstructured":"S.M. Webb, X. Badia, M.J. Barahona, A. Colao, C.J. Strasburger, A. Tabarin et al. Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire. Eur. J. Endocrinol. 158, 623\u2013630 (2008). https:\/\/doi.org\/10.1530\/EJE-07-0762","journal-title":"Eur. J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03128-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03128-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03128-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T15:32:46Z","timestamp":1660750366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03128-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3128"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03128-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Directly related to the present work: E.B., M.F. and R.L. have served on an advisory board for HRA Pharma. S.H. received travel grant from HRA Pharma. Not related to the present work: J.H.: Board (IPSEN, Pharma Mar, Lilly, Roche, AAA), Travel support (AAA, IPSEN), Research: (Novartis). L.L.: tumor board (IPSEN, Bayer, EISAI), Honoraria (EISAI, LILLY), Travel Grant (AAA, Novartis). S.H.: Board (Eisai, AAA), Travel support (Ipsen, AAA), Research (HRA Pharma, Ipsen). E.B.: Expert board (Ipsen, Novartis, AAA, Pfizer, Hutchinson Pharma), Research grant: (Novartis, HRA), Principal investigator (Ipsen), Drug supply (Pfizer, AAA). M.F.: Board (HRA Pharma), Honoraria (VIFOR Pharma), Travel Grant (Novartis, Ipsen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}